Answers are grounded in this paper and cite their sources.
Background/Objectives: SLFN11 is a regulator of cellular sensitivity to DNA-damaging agents, but its role in non-small-cell lung cancer (NSCLC), particularly in the context of radiochemotherapy, remains incompletely understood. This study aimed to evaluate the association of SLFN11 with chemo- and radiosensitivity in NSCLC cell lines and to explore its potential association with clinical outcome in patients with stage III NSCLC treated with platinum-based radiochemotherapy. Methods: SLFN11 expression was analyzed in a genetically diverse panel of NSCLC cell lines. Transient siRNA-mediated SLFN11 knockdown was performed, followed by carboplatin treatment, irradiation, and combined carboplatin–irradiation treatment. Short-term cell viability was assessed using MTS assays, while long-term survival was evaluated by clonogenic assays. Key findings were validated with a second, independent siRNA pool in two SLFN11-high cell lines, and cell cycle distribution and apoptosis were analyzed by flow cytometry. In addition, SLFN11 protein expression was assessed by immunohistochemistry in pretreatment tumor samples from a small, highly selected retrospective subgroup. Results: SLFN11 expression varied markedly across NSCLC cell lines. SLFN11 knockdown was associated with reduced carboplatin sensitivity in selected models, with the most pronounced effects observed in SLFN11-high cell lines. This finding was reproduced with the second siRNA pool and was accompanied by attenuated carboplatin-induced S-phase accumulation and apoptosis, most consistently in HCC15 cells. In contrast, SLFN11 depletion did not consistently alter radiation response or clonogenic survival after irradiation. Combined carboplatin–irradiation treatment largely reflected the effects observed with carboplatin exposure. In the exploratory clinical subgroup, SLFN11 protein expression was not associated with progression-free survival following platinum-based radiochemotherapy. Conclusions: These findings suggest that SLFN11 is associated with platinum-related short-term cytotoxicity and apoptosis, whereas no consistent effect on intrinsic radiosensitivity or long-term clonogenic survival was observed in the analyzed NSCLC models. The clinical analysis should be interpreted as exploratory and hypothesis-generating. Overall, the relevance of SLFN11 as a biomarker appears to be treatment-context-dependent and requires validation in larger, clinically well-defined cohorts.
No takes yet. Share an insight, caveat, or question.
Niemeier et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: